Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for the treatment of glioblastoma (GBM).
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute’s (NCI) Small Business Innovation Research (SBIR) program.
Scientists Wipe Out Aggressive Brain Cancer Tumors by Targeting Cellular ‘Motors’
A potential treatment for glioblastoma developed by UF researchers makes the deadly brain cancer newly sensitive to both radiation and chemotherapy, while also blocking its ability to invade other tissue.
Myosin Therapeutics Receives FDA Clearance To Initiate First-in-Human Trial of MT-125 in Glioblastoma
UF startup Myosin Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for MT-125.
Myosin Therapeutics Closes Second Seed Round To Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies
UF startup Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding round, raising over $3 million to supplement significant investment from the National Institutes of Health.